



**Oncode
Accelerator**

*Outsmarting cancer
Impacting lives*

Accelerating the Development of Cancer Therapies

Small Molecules

State-of-the-Art Infrastructure Backed By Scientific Know-How

Key to the success of the Oncode Accelerator program is the selection and execution of high-quality Demonstrator Projects, which aim to validate the Oncode Accelerator infrastructure while simultaneously addressing unmet medical needs.

By combining the key capabilities of our Workstreams with innovations from our Platforms, we create a synergistic effect resulting in better therapies that are tailored to individual patients or patient subgroups.

Translate Fundamental Discoveries into Cancer Therapies

The Small Molecules Workstream of Onco Accelerator focuses on translating fundamental discoveries into new cancer therapies, while integrating our three innovation Platforms (Patient Cohorts, Organoids and Artificial Intelligence) at different stages of the drug development pipeline.

Keep reading to find out how you can tap into the potential of accelerated small molecule discovery and development, leveraging innovations to de-risk the process.

Accelerate Small Molecule Development Using AI

Drug developers that work with the Onco Accelerator Small Molecules Workstream can make use of automated design and synthesis of drug candidates using Artificial Intelligence (AI). For example, AI can be used to improve hit-to-lead and lead-to-candidate optimization by considering multiple design goals (affinity, selectivity and synthesizability), or to reduce the number of optimization cycles needed — leading to increased throughput and reduced costs.

Placing the Patient at the Core of Small Molecule Development

Leverage well-defined patient cohort data and patient-derived organoid models early in the preclinical stages of the drug development pipeline, and place the patient at the core of your small molecule drug development. This allows for the dynamic adjustment of your small molecule trajectory and supports patient stratification and selection of the right target population, which may help to de-risk the drug development process.

Would You Like To Utilize...

The state-of-the-art facilities from our academic and industry partners?

Highly advanced equipment with leading scientific expertise to be used for various applications such as whole proteome measurements, post-translational modification (PTM) analyses (phospho, acetyl, etc.), and identification of protein-protein interactions?

Apply for a Demonstrator Project and receive up to 50% in co-funding.

What We Offer

- ◆ Produce, purify and characterize proteins
- ◆ Accelerate your lead discovery project with *in silico*, phenotypic and high throughput screening
- ◆ Use medicinal chemistry, structural biology (cryo-EM, X-Ray), ADME-T and pharmacokinetics
- ◆ Use AI to predict the direct and indirect cellular targets of leads and clinical candidates
- ◆ Apply chemical proteomics to study compound cellular selectivity and target engagement
- ◆ Determine the cellular effects of small molecules via proteomics and metabolomics
- ◆ Run microdosing studies to assess pharmacokinetics in a phase 0 study

Work With Us

Through Onco Accelerator, we provide academic researchers, biotech drug developers and industry partners with access to expertise, facilities and technologies aimed at efficient, patient-centered development of cancer therapies up to early clinical validation. We are actively seeking ideas for Demonstrator Projects, through which you can access co-funding and support.

Reach out for more information

 demonstrators@oncodeaccelerator.nl

About Oncode Accelerator

Oncode Accelerator is a public-private partnership funded by the Dutch National Growth Fund (NGF), which aims to innovate and accelerate the preclinical development of new cancer therapies by placing cancer patients at the core. It is a collaboration between six coordinating partners:





**Get to
know us**

www.oncodeaccelerator.nl

 **Oncode Accelerator**